Alnylam is a biopharmaceutical company pioneering RNA interference (RNAi) therapeutics to treat genetic, cardio-metabolic, and hepatic diseases. The company develops and commercializes approved therapies and maintains a pipeline of investigational RNAi medicines delivered primarily via subcutaneous injection. Alnylam focuses on rare diseases and specialty indications with high unmet medical need.
In Q1 2026, 7 tracked hedge funds held Alnylam Pharmaceuticals, Inc.. Net institutional flows were positive at $28,590,347.
| # | Fund | Shares | Value | Weight | Change |
|---|---|---|---|---|---|
| 1 | Millennium Management LLC | 493,087 | 163.15M | 0.06% | +470.5% |
| 2 | Soleus Capital Management LP | 131,650 | 43.56M | 1.76% | +88.1% |
| 3 | Bridgewater Associates | 106,592 | 35.27M | 0.16% | +24.5% |
| 4 | Hudson Bay Capital Management LP | 40,000 | 13.23M | 0.05% | -86.0% |
| 5 | Frontier Capital Management Co LLC | 30,604 | 10.13M | 0.10% | -37.4% |
| 6 | Point72 Asset Management | 6,300 | 2.08M | 0.00% | -43.2% |
| 7 | Verition Fund Management | 898 | 297,121 | 0.00% | -77.6% |